 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MYOS RENS Technology Inc. MYOS or the Company NASDAQ: MYOS in connection with the proposed merger of the Company with privately-held pharmaceutical company MedAvail, Inc. MedAvail. Under the terms of the agreement, all of the assets and liabilities of MYOS with exception to certain excluded assets will be contributed to a subsidiary of MYOS, and shares of that subsidiary will then be distributed as a dividend to MYOS shareholders immediately following the closing of the merger. Ultimately, following the closing of the deal, MYOS shareholders will own only 3.5 of the new combined company, with MedAvails security holders and new investors owning the remaining 96.5 of the new entity. 